Blood & Marrow Transplantation
Message From the Chief
Welcome to the Division of Blood and Marrow Transplantation. We are very proud of the outstanding compassionate care that we provide our patients along with conducting state of the art basic and translational science on stem cell biology, cellular immunology and transplantation biology.
The BMT program at Stanford performs autologous and allogeneic transplantations for over 300 patients each year. The program has been very successful with a history of limited morbidity rates and acute mortality that is well below most published reports.
Make a Gift
Our cutting-edge research is developing novel immunotherapy for cancer. Support the BMT Division by making a donation to our research fund.
In the News
When Kohler and Milstein developed hybridoma technology in 1975, a monoclonal antibody was thought to be the “Magic Bullet” to treat cancer since it can go directly to the targeted cancer cells.
While allogeneic transplantation can be life saving for patients with hematologic malignancies, or inherited disorders such as several forms of immuno-deficiency, the transplant-related side effects and complications remain the biggest hurdles.
While the graft-versus-tumor effect provided by the donor graft can be very powerful in controlling the disease, disease relapse is still the primary reason that patients do not do well after an allogeneic transplantation.
When Robin was first diagnosed with acute myeloid leukemia in December 2011, she knew that it would be a long journey for her fight against this cancer.
DO YOU KNOW?
More than 360 adults have received bone marrow or stem cell transplants at Stanford every year.